

Product Update

fluticasone furoate, umeclidinium, vilanterol (as trifenate) 92 micrograms / 55 micrograms / 22 micrograms inhalation powder (Trelegy® Ellipta®)

SMC No 1303/18

GlaxoSmithKline UK

12 January 2018

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

fluticasone furoate / umeclidinium / vilanterol (as trifenate) (Trelegy® Ellipta®) is accepted for restricted use within NHS Scotland.

Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β 2-agonist.

SMC restriction: in patients with severe COPD (forced expiratory volume in one second [FEV₁] <50% predicted normal).

Trelegy Ellipta costs less than inhalers containing fluticasone furoate / vilanterol (as trifenate) 92 micrograms / 22 micrograms and umeclidinium 55 micrograms administered separately.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 1 December 2017.

Chairman
Scottish Medicines Consortium